Acrivon Therapeutics (Nasdaq: ACRV) announced that its experimental cancer drug ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced into the randomized dose ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE